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• Phenotypic cell differentiation
• Physiological relevance
• Patient-derived models
• Stem cell models




• Size and shape-based viability
• Spatial dependence of physiological state
• Simplified organ models
• Validation uncertain
• No vascularization system
• Dynamic tuning of tumour ecosystem
• Long, complicated cell culture protocols
• Orthogonal cell type
interactions
• Ex vivo clinical trials
• Fluidic systems
• Manipulate the extracellular
matrix
• Expensive
• Challenging model validation
• Current lack of clinical validation
• Incentives and funding
• High physiological relevance
• Available assays
• Novel 3D tissue models
• 4D in vitro pharmacology
• Intelligent screening
• Innovation in biological target
space






• In vitro to in vivo translation
• Data reproducibility
• 3D parameter understanding
• Challenging volumetric analysis
• Ease of use
• Exploit computational
biology methods




• Current equipment is sufficient
• Clearing protocols exist
• In vivo diagnostic technology
analogy
• Limited penetration depth
• Limited holder solutions
• Requirement for object search
• Bleaching of fluorophores
• Multiscale imaging requirement
• Needs optimized equipment
• Image quality
• Long acquisition times
• Optical physics technology 
innovations
• Customized supports
• Development of photostable
fluorophores
• New information-rich data sets




• Limited access of assay reagents
L I N K  TO  O R I G I N A L  A RT I C L E
There is intense excitement in the scientific 
community about 3D cellular model sys-
tems because they promise to resemble and 
recapitulate the in vivo tissue environment 
more faithfully than 2D systems1. A rapidly 
expanding offering of commercially available 
in vitro technologies for high-throughput 3D 
cell-based disease models, combined with 
advances in material sciences, are enabling 
widespread application and adoption of 
these models across academic and industrial 
research groups. However, there is a lack of 
conclusive evidence that such models accu-
rately recapitulate in vivo tissue physiology and 
disease pathophysiology, and thereby provide 
sufficiently quantitative and reproducible data 
to replace current models and improve the clin-
ical success rates of drug candidates. Prominent 
cellular high-content screening (HCS) and bio-
image informatics societies are therefore calling 
for further debate to discuss the value of these 
emerging 3D model systems in an effort to 
establish more transparent and standardized 
guidelines in the field. Specifically, scientific 
community representatives highlight the lack 
of validated methodologies and software tools 
that enable robust quantitative analysis of the 
vast number of newer 3D cellular models.
With this in mind, we conducted a SWOT 
(strengths, weaknesses, opportunities and 
threats) analysis of the pipeline for high-con-
tent analysis of 3D cellular systems, divided 
into the four main stages: system develop-
ment, imaging, screening and data analysis. 
Here, we summarize the main outcomes of 
this SWOT analysis, which are highlighted 
in FIG. 1. Each point is further discussed in 
more depth and references are provided in 
Supplementary Box 1.
SWOT analysis
There have been substantial developments in 
the field of cell-based screening during the 
last decade, such as the emergence of stem cell 
technologies, microtissues, organoid models 
and organ-on-a-chip platforms. Relevant dif-
ferences in cellular behaviour between 2D and 
3D cultures have been characterized in sev-
eral prominent studies, reporting the greater 
physiological relevance of 3D models com-
pared with similar 2D models. In most cases, 
cells are grown embedded in extracellular 
matrices to form organoids or spheroid-like 
structures. However, these models do not 
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Figure 1 | SWOT analysis of the four major steps in high-content screening using 3D cellular systems. For an expanded list of points with references, 
please see Supplementary Box 1. SWOT, strengths, weaknesses, opportunities and threats.
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deeper penetration of light into tissue, but 
many areas require improvement, especially 
if 3D imaging is to be applied in HCS. 
Given the vast amount of data generated 
in a high-content screening campaign, every 
byte is precious and therefore every pixel 
has to be of the highest quality. Importantly, 
given the need for extensive functional and 
mechanistic studies, the need to develop bet-
ter imaging techniques and the vast amount of 
data produced in screens, our analysis high-
lights the lack of user-friendly analytical tools. 
Open-source algorithms for 3D image analy-
sis, visualization and statistical analysis exist, 
but they are not accessible to biologists and 
require extensive computational expertise. 
This represents a major hurdle for the adop-
tion, development and validation of advanced 
3D model systems (see Supplementary Box 
information S1 for more detail).
Conclusion
We believe there is a need for more early mul-
tidisciplinary collaborations, methodology 
guidelines, better communication and edu-
cation in this field to provide the community 
with a more transparent assessment of the 
value of new 3D models and a customized 
toolkit for the users of 3D technologies. In 
addition, we call for collaborative 3D cellular 
model development between industry and 
academia to promote the adoption of stan-
dardized 3D assay technologies. 
We also wish to emphasize that it is not 
beneficial for the field to oversell currently 
available models because they have neither 
been clinically validated nor are they likely 
complex enough to mimic in vivo physiology 
faithfully. We have often witnessed an early 
enthusiasm for technologies followed by disil-
lusionment due to inflated expectations and 
disappointing results. In retrospect, it was 
clear that the technology was not mature and 
needed further research and development in 
order to better understand its shortcomings 
and strengths. Similarly, with 3D cell culture 
systems, we run the risk of disillusionment if 
we do not establish appropriate guidelines on 
how to validate a model, how to cultivate the 
cells, how to acquire the image data and how 
to analyse the resulting data. Nevertheless, 
with awareness of their limitations and con-
certed efforts to close the gaps in validating 
the relevance of 3D cell model systems and 
associated technologies, such systems may 
enable important advances in drug discovery 
and fundamental biology. 
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fully represent the complexity of many in vivo 
tissues, often lacking relevant cell types and 
required growth factors, and are not subject 
to long-distance signalling from other organs, 
the immune system, the endocrine system 
or the microbiome. In particular, the most 
current models are static and do not model 
the dynamics of in vivo tissue perfusion and 
mechanical stress forces. Emerging microflu-
idic and macrofluidic technologies that simu-
late a circulatory system allow perfusion of 3D 
tissues, and can induce shearing forces while 
permitting the observation of the microtis-
sue at the same time. However, the majority 
of systems so far have not been designed for 
automated screening applications and cur-
rently there is no off-the-shelf solution com-
patible with conventional HCS platforms. 
One of the next challenges will therefore be 
miniaturizing these systems in order to screen 
hundreds to thousands of microtissues at the 
same time in a cost-effective manner.
At present, there is still a lack of both quali-
tative and quantitative evidence demonstrat-
ing that such 3D model systems better predict 
clinical response relative to existing in vivo 
approaches. So, although the advantages of 3D 
model systems appear to be clear, we caution 
not to overestimate their physiological rel-
evance given their relative simplicity in com-
parison to in vivo tissues. We also strongly 
encourage further development, validation, 
and investment in comparative phenotypic, 
genomic, proteomic and metabolomic analy-
sis between new 3D model systems with both 
healthy and diseased human tissues. 
Imaging of 3D model systems poses sub-
stantial challenges owing to light scattering 
within the objects and the non-uniform posi-
tioning of objects in microplate wells. These 
challenges can be partially addressed with 
smart techniques on automated microscopes 
and chemical clearing protocols to allow 
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